ABSTRACT
Objective: To study the effect of intracavitary infusion of Huachansu injection combined with polysaccharide nucleic acid fraction of Bacillus Calmette Guérin (BCG-PSN) or cisplatin in the treatment of the malignant pleural and peritoneal effusions. Methods: Seventy patients were randomly divided into two groups. Patients in the treatment group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 18 mL of BCG-PSN; patients in the control group (n = 35) were intracavitarily infused with 20 mL of Huachansu injection and 60 mg of cisplatin once a week and the treatment lasted for 2-4 weeks. Results: For the treatment group, the response rate (complete response + partial response) was 83.3% in 24 cases with malignant pleural effusion and 63.6% in 11 cases with malignant peritoneal effusion. The total response rate was 77.1% (27/35) in the treatment group. The KPS score was elevated in 26 cases, stable in 7 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 69.2% in 13 cases with malignant peritoneal effusion. The total response rate was 80.0% (28/35). The KPS score was increased in 16 cases, stable in 11 cases, and decreased in 8 cases. There was no significant difference in clinical efficacy between the two groups (P > 0.05). Patients in the treatment group had less adverse reaction and a more improved living quality than those in the control group (P < 0.05). Conclusion: Intracavitary infusion of Huachansu injection combined with BCG-PSN or cisplatin was effective in the treatment of malignant pleural and peritoneal effusions, but Huachansu injection plus BCG-PSN had less toxicity especially for the advanced patients who can not tolerate the intracavitary chemotherapy.
ABSTRACT
Objective: To observe the effect of intrapericardial infusion of Huachansu and cisplatin in the treatment of the malignant pleural effusion and ascites. Methods: The sixty six patients were randomly divided into two groups. Patients in the treatment group (n = 33) were infused with 20 mL of Huachansu injection and 60 mg of cisplatin intrapericardially once a week and the treatment lasted for 24 weeks. Patients in the control group (n = 33) were infused with 60 mg of cisplatin intrapericardially. Results: For the treatment group, the response rate (complete response + partial response) was 86.4% in 22 cases with malignant pleural effusion and 72.7% (8/11) in 11 cases with malignant ascites. The total response rate was 81. 8% (27/33). The living qualities were improved in 21 cases, stable in 10 cases, and decreased in 2 cases. For the control group, the response rate (complete response + partial response) was 52.4% in 21 cases with malignant pleural effusion and 41.7% in 12 cases with malignant ascites. The total response rate was 48.5%. The living qualities were improved in 9 cases, stable in 12 cases, and decreased in 12 cases. The response rate was significantly higher and the toxic reaction was significantly lower in the treatment group than that in the control group (P < 0.05). Conclusion: Intraperi-cardial infusion of Huachansu injection plus cisplatin achieves satisfactory effects in the treatment of malignant pleural effusion and ascites and has less side effects. It is worthy of clinical application.